NASDAQ · ELEV
Healthcare · Biotechnology
$0.37
Down-$0.01 (-2.12%)
Updated Aug 15, 2026, 12:11 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ELEV does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ELEV.
ELEV research
Company profile and research snapshot.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 10, 2025 | JMP Securities | Market Perform | — |
| Jun 10, 2025 | HC Wainwright & Co. | Neutral | — |
| Jun 9, 2025 | William Blair | Market Perform | — |
| Mar 24, 2025 | Stephens & Co. | Equal-Weight | — |
| Mar 21, 2025 | Citizens Capital Markets | Market Perform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 15, 2025
Class action attorney Juan Monteverde is investigating the mergers of Elevation Oncology, Atai Life Sciences, and Blueprint Medicines, to determine if the proposed deals are fair for shareholders.
Benzinga · Jun 9, 2023
U.S. stocks traded pared some gains midway through trading, with Dow Jones turning lower on Friday. The Dow traded down 0.07% to 33,810.44 while the NASDAQ rose 0.17% to 13,260.91. The S&P 500, also rose, gaining, 0.06% to 4,296.69. Check This Out: $1M Bet On This Tech Stock? Check Out These 3 Stocks Insiders Are Buying Leading and Lagging Sectors Consumer discretionary shares jumped by 0.6% on Friday. Meanwhile, top gainers in the sector included Farfetch Limited (NYSE: FTCH), up 8%, and BARK, Inc. (NYSE: BARK), up 10%. In trading on Friday, materials shares fell by 1%. Top Headline Tesla, Inc. (NASDAQ: TSLA) shares gained over 5% on Friday after Wedbush added the stock to its best ideas list and raised its price target from $215 to $300. Equities Trading UP Braze, Inc. (NASDAQ: BRZE) shares shot up 22% to $41.40 after the company posted upbeat first-quarter results and issued strong forecast. Shares of Disc Medicine Opco Inc (NASDAQ: IRON) got a boost, shooting 23% to $48.41 after the company ...
Benzinga · May 30, 2023
Keybanc boosted the price target for Broadcom Inc. (NASDAQ: AVGO) from $720 to $820. Keybanc analyst John Vinh maintained the stock with an Overweight rating. Broadcom shares rose 11.5% to close at $812.73 on Friday. Telsey Advisory Group cut the price target for Big Lots, Inc. (NYSE: BIG) from $9 to $6. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Big Lots shares fell 2.6% to $6.09 in pre-market trading. Barclays cut the price target for Ulta Beauty, Inc. (NASDAQ: ULTA) from $636 to $600. Barclays analyst Adrienne Yih maintained an Overweight rating. Ulta Beauty shares fell 0.1% to $419.85 in pre-market trading. Baird cut Hibbett, Inc. (NASDAQ: HIBB) price target from $70 to $50. Baird ...
Zacks Investment Research · Mar 23, 2023
Here is how Elevation Oncology, Inc. (ELEV) and Senesco Technologies Inc. (ELOX) have performed compared to their sector so far this year.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELEV.
No results
No recent SID articles mention ELEV.
